Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study

LEI YUAN1*, JUN HAN1*, QINGYANG MENG1, QIULEI XI1, QIULIN ZHUANG1, YI JIANG1, YUSONG HAN1, BO ZHANG1, JING FANG2 and GUOHAO WU1

1Department of General Surgery, Zhongshan Hospital, Fudan University; 2Key Laboratory of Food Safety Research, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, P.R. China

Received December 8, 2014; Accepted February 9, 2015

DOI: 10.3892/or.2015.3845

Abstract. Muscle atrophy F-Box (MAFbx)/atrogin-1 and muscle ring-finger-1 (MuRF-1) have been identified as two muscle-specific E3 ubiquitin ligases that are highly expressed in skeletal muscle during muscle atrophy. However, the role of muscle-specific E3 ubiquitin ligases during the process of muscle atrophy of cancer cachexia remains largely unknown. In the present study, we analyzed the expression of atrogin-1 and MuRF-1 in the skeletal muscle of patients with malignant and benign disease. The possible mechanisms were studied both in a colon 26-induced cancer cachexia mouse model and in tumor necrosis factor-α (TNF-α) induced atrophy C2C12 cells. Our results demonstrated that atrogin-1 and MuRF-1 tended to be increased in the skeletal muscle of patients with malignant disease even before weight loss. Non-tumor body weights and gastrocnemius weights were significantly decreased while expression levels of ubiquitin proteasome pathway associated genes (atrogin-1, MuRF-1, ubiquitin and E2-14K) were upregulated in cancer cachexia mice. Significant myotube atrophy with atrogin-1 overexpression was observed in the C2C12 cells treated with TNF-α. Meanwhile, knockdown of atrogin-1 by small interfering RNA (siRNA) protected C2C12 cells from the adverse effect of TNF-α. In conclusion, muscle-specific E3 ubiquitin ligases were upregulated during cancer cachexia, and atrogin-1 may be a potential molecular target for treating muscle atrophy induced by cancer cachexia.

Introduction

Cancer cachexia, a condition of advanced protein calorie malnutrition, is characterized by loss of skeletal muscle protein, depletion of lipid storage, anorexia, poor performance and ultimately death (1-3). Cancer cachexia occurs in ~80% of cancer patients and is the primary cause of death for 22-30% of all cancer patients (3,4). However, cancer cachexia is difficult to diagnose until patients have lost more than 5-7% of their body weight (5,6). Furthermore, it was reported that 80% of patients with upper gastrointestinal cancers and 60% of patients with lung cancer had already experienced substantial weight loss at the moment of diagnosis (7). Therefore, it is essential to illuminate the early mechanisms in the development of cancer cachexia.

The pathogenesis of cancer cachexia including alterations in energy and substrate metabolisms is multifunctional. Skeletal muscle protein depletion (i.e. muscle atrophy) due to hyper-catabolism is the most common characteristic of cancer cachexia. Cancer cachexia is a complex process that occurs as a consequence of a variety of stressors including neural inactivity, mechanical unloading, inflammation, metabolic stress and elevated glucocorticoids (1,8,9). Several proteolytic systems, such as the lysosome, the calcium-dependent systems and the ubiquitin-dependent systems are involved in degrading skeletal muscle (8). However, it was reported that ubiquitin dependent proteolysis is the main mechanism for the enhanced muscle protein degradation in cancer cachexia (10). In addition, cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6) and interferon-γ (IFN-γ) have been proposed as mediators for the cancer cachetic process (3,11,12).

The ubiquitin-dependent proteasome pathway includes a series of reactions involving three classes of proteins: ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin protein ligases (E3) (13). Muscle atrophy F-Box (MAFbx)/atrogin-1 and muscle ring-finger-1 (MuRF-1), identified over 10 years ago, are two muscle-specific E3 ubiquitin ligases that are increased in skeletal muscle under atrophy-inducing conditions such as humans under voluntary bed rest (14) or with spinal cord injury (15), amyotrophic lateral sclerosis (16), chronic obstructive pulmonary disease...
(COPD) (17) and in animal models of aging (18), diabetes (19), starvation (20), making them excellent markers for muscle atrophy. However, little is known concerning the role of muscle-specific E3 ubiquitin ligase genes during the process of cancer cachexia.

The goal of the present study was to elucidate the role of muscle-specific E3 ubiquitin ligases during cancer cachexia \textit{in vitro} and \textit{in vivo}. Firstly, we determined the expression of muscle-specific E3 ubiquitin ligases both in patients with malignant and benign disease. Furthermore, in a mouse model of cancer cachexia, we analyzed the expression of muscle-specific E3 ubiquitin ligases and other ubiquitin proteasome pathway-associated genes. Finally, we illustrated the protective effect of atrogin-1 small interfering RNA (siRNA) in an atrophy model of muscle cells induced by TNF-\(\alpha\). Our results showed that muscle-specific E3 ubiquitin ligases were upregulated both in humans with malignant disease and mice with cancer cachexia. Atrogin-1 gene silencing protected myotubes from atrophy induced by TNF-\(\alpha\). We believe that such a comprehensive analysis of muscle-specific E3 during cancer cachexia in clinical patients to an animal model and muscle cells illuminated the importance of muscle-specific E3 during cancer cachexia and may provide novel targets for drug discovery in the intervention of the progression of cancer cachexia.

Materials and methods

Patients and muscle samples. Twenty-one patients with malignant disease admitted to Zhongshan Hospital of Fudan University between August 2011 and December 2013 were enrolled in the present study. Diagnoses of malignant disease were confirmed by postoperative pathological examinations. Twenty-three patients undergoing surgery for benign abdominal diseases served as the control group. Exclusion criteria included patients with acute or chronic renal and liver failure, severe sepsis, AIDS, inflammatory bowel disease, autoimmune diseases, diabetes, metabolic acidosis, acute and chronic hepatitis, and chronic heart failure.

Animals and treatments. BALB/c male mice (6-8 week of age) weighing 16-20 g were purchased from the Shanghai Laboratory Animal Center, Chinese Academy of Sciences. Mice were housed at 22±1˚C, with a 12-h light/dark cycle, free access to water and conventional diet. Mice were acclimated to the environment for one week before the study started. All animal manipulations were carried out according to the guidelines of regulations for the use of experimental animals of the Chinese Academy of Science. All efforts were made to minimize animal suffering and to use only the number of animals necessary to produce reliable scientific data.

Colon 26/clone 20 cells, which have been reported to induce severe cachexia in BALB/c mice by subcutaneous inoculation, were purchased from the Shanghai Institute of Pharmaceutical Industry. The cells were cultured in RPMI-1640 supplemented with 5% fetal bovine serum and 1% penicillin-streptomycin at 37˚C in 5% CO\(_2\). On study day 0, 1.0x10\(^6\) cells suspended in 100 ml phosphate-buffered saline (PBS) were injected subcutaneously into the armpits of the mice in the tumor group. An equal volume of PBS without tumor cells was injected into the control group mice. The body weight of each mouse was recorded every two days after tumor cell inoculation. On day 16, the mice were sacrificed via cervical dislocation. Non-tumor body weights and gastrocnemius muscle weights were recorded. Muscle specimens were frozen at -70˚C for further analysis.

Cell lines and treatment \textit{in vitro}. Mouse skeletal muscle C2C12 cells were propagated and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with antibiotics and 10% fetal bovine serum at 37˚C in the presence of 5% CO\(_2\). To induce differentiation, C2C12 cells were propagated in DMEM supplemented with antibiotics and 2% horse serum for the indicated period. After 3 days of differentiation, according to a previous report (22), C2C12 cells were treated with 10 ng/ml recombinant mouse TNF-\(\alpha\) (R&D Systems, USA) for 96 h to extract proteins, and C2C12 cells were treated with 6 ng/ml recombinant mouse TNF-\(\alpha\) for 2 h to extract RNAs.

Construction and infection of the lentivirus containing siRNA targeting the human atrogin-1 gene. Five pairs of siRNAs targeting the human atrogin-1 gene (Table I) were designed using Ambion siRNA Target Finder and were synthesized by Invitrogen Biotechnology Co., Ltd. (Shanghai, China). In addition, negative control siRNA was also synthesized for monitoring the influence of the exogenous genes. These siRNAs were cloned into vector pBS-hU6-I and then into vector FG12. The length and accuracy of the sequences were confirmed by DNA sequencing. The recombinant FG12 vectors were cotransfected with pRSVRE, pMDLg/pRRE and pHCMV-G into 293T cells to package lentivirus particles, with which C2C12 cells were infected. The infected C2C12 cells were cultured and differentiated to form myotubes before TNF-\(\alpha\) was added to induce atrophy. Atrogin-1 mRNA and protein were identified by real-time PCR (RT-qPCR) and western blotting, respectively. Myotube morphology was observed and photographed directly in the culture plate without fixation.

Western blot analysis. Total proteins were extracted from cells or muscle tissues and quantified by the BCA method. Western blotting was performed to determine the protein expression of atrogin-1. The protocol used for western blotting was previously described (23). Briefly, 50 mg total proteins was separated by SDS-PAGE, transferred to PVDF membranes, and analyzed by western blotting with a goat polyclonal anti-human atrogin-1 antibody (Santa Cruz Biotechnology, USA). An antibody against \(\alpha\)-tubulin (Santa Cruz Biotechnology) served as an endogenous control. Finally, the membrane was visualized by an imaging system in the dark to quantify the protein level.
RNA extraction and RT-qPCR analysis. Total RNAs were isolated from the cells or tissues with TRIzol (Invitrogen, Carlsbad, CA, USA). RNA integrity was detected by an agarose gel method, and the RNA concentration was quantified by measuring A260 and A280 absorbance in a NanoDrop spectrophotometer (Thermo Scientific, USA). cDNA synthesis was carried out with 2 µg of total RNAs by reverse transcription (RT) (Promega, Madison, WI, USA). RT-qPCR was performed using 7900HT Fast Real-Time PCR System (Applied Biosystems, Inc., Foster City, CA, USA). Real-time Master Mix (Toyobo, Osaka, Japan) was used to detect and quantify the expression levels of the target genes. The PCR reaction consisted of an initial denaturation at 95˚C for 10 min followed by 40 cycles of 30 sec at 95˚C, 10 sec at 60˚C and 30 sec at 72˚C, and finally 10 min at 72˚C. Amplification of the target cDNA was normalized to β-actin expression. Relative levels of target mRNA expression were calculated using the 2^(-ΔΔCt) method. The primers used are listed in Table II.

Immunohistochemical staining. Immunohistochemical staining (IHC) of the tissues was performed as previously described (23). Briefly, muscle tissues were fixed in 4% formalin for 24 h and paraffin-embedded using a conventional method. Sections (3-µm) were dehydrated in xylene and graded alcohols. Antigen retrieval was performed with 0.01 M citrate buffer at pH 6.0 at 95˚C for 20 min. The slides were then incubated with atrogin-1 antibody at 4˚C overnight and then with the fluorescein isothiocyanate (FITC)-conjugated secondary antibodies for 60 min at room temperature in the dark.

Statistical analysis. Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, USA). Continuous variables were compared using the Student's t-test and are expressed as the mean and standard deviation (SD). P<0.05 was considered to indicate a statistically significant result.
Results

Atrogin-1 and MuRF1 mRNA are highly expressed in the patients with malignant disease. The clinical characteristics of the patients with malignant disease and benign disease are shown in Table III. Nutrition statuses such as BMI, total lymphocyte count, serum albumin and pre-albumin were significantly different in the two groups (P<0.05), while other characteristics showed no significant differences.

The mRNA levels of atrogin-1 and MuRF-1 in the rectus abdominis muscles were analyzed by RT-qPCR. Considering the mean ΔCt of the benign disease group as control, we determined the ΔCt of atrogin-1 and MuRF-1 in the malignant disease group. As shown in Fig. 1A and B, atrogin-1 and MuRF-1 mRNA levels were increased in 66.7% (14/21) and 76.2% (16/21) of the malignant disease patients, respectively. Univariate analysis indicated that the atrogin-1 and MuRF-1 mRNA levels were significantly highly expressed in the malignant disease patients (P<0.05, data not shown). In addition, to determine whether the expression of atrogin-1 and MuRF-1 mRNA increased before weight loss, we compared the mRNA levels of atrogin-1 and MuRF-1 in 16 malignant disease patients and 23 benign disease patients without weight loss. The results showed that both atrogin-1 and MuRF-1 mRNA levels tended to increase in the malignant disease patients but without statistical difference (P=0.099, P=0.132, respectively, Fig. 1C and D).

Table III. Characteristics of the included patients.

<table>
<thead>
<tr>
<th></th>
<th>Malignant disease group (n=21)</th>
<th>Benign disease group (n=23)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years</td>
<td>59.4±11.2</td>
<td>53.8±10.9</td>
<td>NS</td>
</tr>
<tr>
<td>Gender (M:F)</td>
<td>14:7</td>
<td>17:6</td>
<td>NS</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>61.1±9.2</td>
<td>63.4±10.4</td>
<td>NS</td>
</tr>
<tr>
<td>BMI</td>
<td>20.5±2.9</td>
<td>22.5±3.1</td>
<td>0.03</td>
</tr>
<tr>
<td>Weight loss, n/total</td>
<td>6/21</td>
<td>0/23</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total lymphocyte count, x10^9/l</td>
<td>1.5±0.7</td>
<td>1.6±0.6</td>
<td>NS</td>
</tr>
<tr>
<td>Serum albumin, g/l</td>
<td>39.9±5.3</td>
<td>44.2±4.3</td>
<td>0.004</td>
</tr>
<tr>
<td>Serum pre-albumin, g/l</td>
<td>0.21±0.06</td>
<td>0.28±0.04</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

NS, not significant; M, male; F, female; BMI, body mass index.
Successful construction of the colon-26 adenocarcinoma cell-induced cachexia mouse model. Subcutaneous tumors could be touched by hand four days after colon-26 adenocarcinoma cell inoculation and reached ~8 cm³ when the mice were sacrificed. As shown in Fig. 2A, the whole body weight of the tumor-bearing mice increased slowly at the beginning but had a rapid growth afterwards due to the rapid growth of the subcutaneous tumors. Non-tumor body weight of the tumor-bearing mice was significantly less than the control. Gastocnenius muscle weight of the tumor-bearing mice was significantly less than the control. *Significant difference (P<0.05) between the two groups.

Ubiquitin proteasome pathway-associated genes are highly expressed in the cachexia mice. We determined the expression of four ubiquitin proteasome pathway-associated genes (atrogin-1, MuRF-1, ubiquitin and E2-14K) in gastrocnemius muscles of mice. Compared to the non-tumor mouse, atrogin-1, MuRF-1, ubiquitin and E2-14K mRNA levels were significantly increased in the cachexia mice (P<0.05, Fig. 3A). Western blotting and IHC confirmed that atrogin-1 protein was overexpressed in the cachexia mice (magnification, x400).

Optimization of the lentiviral vector system for siRNAs targeting atrogin-1. The accuracy of the recombinant plasmids
was confirmed by DNA sequencing. Two correct recombinant plasmids PBSU6I-atrogin-1 siRNA-1 and -2 were chosen for further analysis, while three incorrect recombinant plasmids PBSU6I-atrogin-1 siRNA-3, -4 and -5 were discarded. After transfection with the recombinant lentivirus vector expressing atrogin-1 siRNA-1 and -2, atrogin-1 was downregulated in the C2C12 cells. However, only atrogin-1 siRNA-1 was identified to be the most effective siRNA in inhibiting atrogin-1 expression. As shown in Fig. 4, atrogin-1 was downregulated in the C2C12 cells transfected with atrogin-1 siRNA-1 and -2 compared to the non-specific siRNA control, yet only siRNA-1 significantly downregulated the expression of atrogin-1 (P<0.05). Thus, we chose siRNA-1 for subsequent study.

**TNF-α induces myotube atrophy and atrogin-1 is overexpressed in the C2C12 cells.** After treatment with 10 ng/ml TNF-α, the C2C12 cells grew slowly and myotubes atrophied with a significantly decreased diameter (Fig. 5A and B). Atrogin-1 was significantly increased at the mRNA and protein levels after treatment with 6 ng/ml TNF-α for 2 h and 10 ng/ml TNF-α for 96 h, respectively (Fig. 5C and D).

**Atrogin-1 siRNA-1 reduces myotube atrophy induced by TNF-α in the C2C12 cells.** To investigate whether inhibition of atrogin-1 affects myotube atrophy induced by TNF-α, we compared the myotube morphology and myotube diameter in the C2C12 cells in the atrogin-1 siRNA-1 group and the non-specific siRNA control group. No differences were observed in the two groups before incubation with TNF-α. However, after treatment with TNF-α, the myotubes underwent atrophy with a significant decrease in myotube diameter.
Discussion

In the present study, we demonstrated the involvement of the muscle-specific E3 ubiquitin ligases in muscle atrophy of cancer cachexia in clinical patients, a mouse model and C2C12 cells. To the best of our knowledge, we firstly report that atrogin-1 and MuRF-1 mRNA were found to be upregulated in malignant disease patients even before body weight loss. Additionally, due to tissue limitation, the protein levels of either atrogin-1 or MuRF-1 could not be determined in clinical patients. Thirdly, in the mechanistic study, we only focused on the effect of atrogin-1 but not of all associated genes. Studies to investigate the effect and mechanism of other associated genes should be conducted in the future.

In conclusion, the present study demonstrated that atrogin-1 and MuRF-1 are highly expressed in malignant disease patients and cancer cachexia mice. Interestingly, knockdown of atrogin-1 protected myotubes from atrophy induced by TNF-α in C2C12 cells. The results suggest that knockdown of atrogin-1 may be an effective method to treat muscle atrophy induced by TNF-α in cancer cachexia.

Although our results suggest that muscle-specific ubiquitin ligase E3 may contribute to the muscle atrophy of cancer cachexia, there are several limitations to the present study. Firstly, due to the rare number of cancer cachexia patients, we did not analyze the atrogin-1 and MuRF-1 expression restricted to cancer cachexia patients, but in several types of malignant disease patients. Secondly, due to tissue limitation, the protein levels of either atrogin-1 or MuRF-1 could not be determined in clinical patients. Thirdly, in the mechanistic study, we only focused on the effect of atrogin-1 but not of all associated genes. Studies to investigate the effect and mechanism of other associated genes should be conducted in the future.

In conclusion, the present study demonstrated that atrogin-1 and MuRF-1 are highly expressed in malignant disease patients and cancer cachexia mice. Additionally, knockdown of atrogin-1 protected myotubes from atrophy induced by TNF-α in C2C12 cells. Given the fact that atrogin-1 and MuRF-1 tend to be upregulated even before visible body weight loss in malignant disease patients, future research may focus on the role of atrogin-1 and MuRF-1 in the early stage of muscle atrophy in cancer cachexia and how to exert the anti-cachectic effects of atrogin-1 and MuRF-1 antagonists. Taken together, our data suggest that targeting atrogin-1 at an early stage of muscle atrophy may be an effective strategy for molecular and clinical intervention in the muscle wasting pathological process in cancer cachexia.
Acknowledgements

The present study was supported by the National Natural Science Foundation of China grants (no 30571819).

References